I am a healthcare professional


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.


For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
May 19 / Springer Healthcare

2021 ARVO Annual Meeting In-depth Report


This ARVO 2021 in-depth report provides an overview of recent advances in the aetiology, diagnosis and treatment of diabetic macular edema, geographic atrophy and neovascular age-related macular degeneration.

Association for Research in Vision and Ophthalmology

ARVO Annual Meeting In-depth Report

May 1st – 7th, 2021

In-Depth Report

Welcome to ARVO 2021

ARVO President Stephen C. Pflugfelder

Stephen C. Pflugfelder, ARVO President

Delegates attending ARVO 2021 were welcomed by Immediate Past President, Daniel W. Stamer, Durham, USA, and ARVO President, Stephen C. Pflugfelder, Houston, Texas. Despite the many obstacles brought on by the COVID-19 pandemic, Daniel W. Stamer and Stephen C. Pflugfleder highlighted that technology has connected researchers from around the globe, with the occurrence of virtual lectures, laboratory meetings, symposia, and international meetings such as ARVO 2021 facilitating the exchange of ideas and research.

Daniel W. Stamer thanked the ARVO staff for all their efforts in organising ARVO 2021, who were forced to adapt to the ever-dynamic conditions associated with the pandemic.


Immediate Past President
“We have all faced unexpected challenges over the past year, but despite the hardships, our researchers have endured from the pandemic. We stand strong as a global community”

Daniel W. Stamer, Immediate Past President, Durham, USA

COVID-19 and the eye

Over the last year, extensive research has furthered our understanding of COVID-19, with emerging evidence indicating the potential involvement of the eye in the infection and transmission of COVID-19. Rupesh Agrawal, Novena, Singapore, presented data on the ocular surface and intraocular manifestations of COVID-19, providing an overview of research into COVID-19 transmission via tears and conjunctival secretions. He highlighted results from a recent study which found a significant increase in choroidal thickness (p=0.0175), as well as a significant reduction in the choroidal vascularity index (p=0.0069) in patients with COVID-19, demonstrating ocular involvement of COVID-19 infection. In order to understand the mechanisms of ocular COVID-19 infection, however, further research is needed, and COVID-19 patients presenting with ocular symptoms should be thoroughly assessed by an ophthalmologist.

Seven of the most common ocular manifestations due to COVID-19 reported

Reported ocular manifestations due to COVID-19

Elia Duh, Maryland, USA, outlined research which explored the extent to which ocular surface cells may be susceptible to COVID-19 infection, including whether these cells express key determinants for viral entry. Critical host entry factors ACE2 and TMPRSS2 were investigated using immunohistochemistry and western blotting. ACE2 was present in all specimens in the cornea, limbus, and conjunctiva, while TMPRSS2 staining was observed in all specimens and expressed throughout the entire conjunctival epithelial layer. Dr Duh concluded that the expression of ACE2 and TMPRSS2 demonstrates some susceptibility of the ocular surface to COVID-19 infection, indicating that the eyes may act as an additional infection gateway. These findings support the need for the use of eye protection for healthcare professionals and those at high risk of COVID-19.

“Expression of critical host entry factors supports the likelihood that the ocular surface can be infected by SARS CoV-2, although to a much lesser degree than nasal/respiratory passages”

Elia Duh, Maryland, USA

Timothy Blenkinsop, New York, USA, presented results from a study which sought to investigate the role of productive COVID-19 replication on the ocular surface. Using whole transciptome RNA sequencing in ocular cells, host response to infection and viral replication were assessed.

Limbus cells were found to be at the highest risk for COVID-19 infection when compared with the central cornea. Furthermore, their findings indicated that COVID-19 antagonises the innate immune response while suppressing normal gene transcription.

Accuracy of a mobile phone assay to detect COVID-19 RNA samples

The use of mobile phone technology as an alternative to plate readers in the detection of COVID-19 was proposed by Melanie Ott, California, USA. Her team’s research uncovered that when comparing the two in terms of noise level, the mobile phone outperformed the plate reader with higher consistency, and with around ten times enhanced sensitivity. The researchers subsequently demonstrated that their mobile phone assay could accurately detect 5 out of 5 of COVID-19 RNA samples within 5 minutes in a variant-insensitive manner. Dr Ott further outlined the ongoing review of a test designed to process RNA from a nasal swab sample using a mobile phone camera to detect the presence of COVID-19. If successful, this technology could be rapidly adapted to existing viruses, such as influenza, and novel viruses which may emerge in future.

“We need to invest into novel ways to treat and detect viruses in the future in order to be prepared”

Melanie Ott, California, USA

How a mobile phone COVID-19 test can be applied and adapted

A mobile phone-based COVID-19 test can be applied and adapted to other viruses


Diabetic retinopathy

Diabetic retinopathy (DR) is the 5th most common cause of blindness globally, and accounted for 1 in every 39 people with blindness in 2010. In the last two decades, blindness caused by DR increased in all world regions, within the exception of Western Europe and economically developed North America, who saw a slight decrease in DR cases. Improved glycaemic control and the introduction of DR screening programs have proven effective in the avoidance of DR-related blindness.

The future of diabetic retinopathy care

Lloyd Aiello, Massachusetts, USA, provided an overview of diabetes and its related health complications such as DR and diabetic macular edema (DME). He explored evidence supporting anti-VEGF treatment as a future therapeutic option for non-proliferative DR. Recent studies have demonstrated that those treated with anti-VEGFs show substantially better improvement in retinopathy severity from baseline when compared to those in a sham group (nominal p<0.0001), and also show substantially lower rates of worsening (nominal p<0.001). Anti-VEGF treatment also correlated with a reduced likelihood of vision-threatening complications and centre-involved DME (nominal p<0.001).

However, lack of patient awareness remains a major hurdle in DR therapy, owing to a large reported discrepancy between retinal disease state and patient-reported awareness, with 42% of 18,341 patients found to be unware of any DR even post-follow-up with a retinal specialist.

“Lack of patient awareness is considered a major contributing factor for non-adherence to eye care guidelines and poor visual outcomes”

Lloyd Aiello, Massachusetts, USA

Tien Wong, Singapore, presented the history and evolution of DR and age-related macular edema (AMD) imaging and classification, from the Airlie House Classification of DR, developed in 1968, to the International Diabetic Retinopathy Severity Scale (DRSS). The International DRSS was developed in the 2000s, and is now widely used by clinicians and physicians for the assessment and diagnosis of DR.

Why is there a need for new AMD/DR classifications?

Professor Wong further explained the present need for new classification systems for both DR and AMD due to new imaging technologies, biomarkers, treatments, and clinically-relevant outcomes.

The ideal features of a new classification system would include a clearly defined aim of the system – whether it is intended for research or clinical use – and would be:

Key aims of a new classification system for AMD and DR

Key aims of a new classification system for AMD and DR

Tunde Peto, Belfast, Ireland, discussed the future of teleophthalmology in the treatment of DR. The COVID-19 pandemic has accelerated the implementation of virtual consultations as well as optical coherence tomography home monitoring in healthcare. Wide-field cameras now also provide the option for patients to capture their own images, or for a photographer to use a long lead in order to facilitate social distancing. Such technologies may open the doors to drive-through retinal imaging. This would allow patients to be imaged and diagnosed in their own vehicle using AI software, a similar system to that used currently for drive-through glaucoma testing, therefore protecting both patients and healthcare providers.

The roles of mitochondrial homeostasis and epigenomics in mitochondrial genomic and functional stability in DR were highlighted by Renu Kowluru, Michigan, USA. She illustrated the processes by which epigenetic modifications may cause mitochondrial DNA and structure to become more vulnerable to damage via DNA methylation. Innovative therapies such as histone deacetylase/methyltransferase inhibitors and DNA methylating agents are in the process of being trialled as preventative treatments in DR through protecting mitochondrial homeostasis.


Age-related macular degeneration

A symposium was dedicated to Professors Ron and Barbara Klein, whose combined work yielded crucial insights into the epidemiology of both AMD and DR. Professors Ron and Barbara Klein contributed to ground-breaking studies such as the Beaver Dam Eye Study (BDES) and the Wisconsin Epidemiology Study of Diabetic Retinopathy.

AMD is the primary cause of blindness in adults over 60-years-old, and is associated with loss of central vision, leading to difficulties in reading, driving, facial recognition, amongst other activities of daily living. Common risk factors include genetic background, smoking and obesity. However, the primary risk factor for AMD is ageing. From a genetic perspective, AMD is the most understood complex age-related disorder. Despite this knowledge, effective treatments for the most prevalent disease forms remain elusive.

Timeline of developments in AMD and BDES from 1992 to 2019

Timeline of developments in AMD and BDES

Caroline Klaver, Rotterdam, Netherlands, recounted the seminal BDES and its impact on AMD studies today. The 3 Continent Consortium built upon the BDES with a focus on epidemiology and risk factors for AMD. They confirmed an association with smoking (OR = 4.6; 95% CI 2.7–7.5), and a synergistic effect between smoking, fish, and lutein intake in AMD. Later, the EYE-RISK consortium investigated the genetic bases of AMD. When assessing ORs for AMD risk alleles as a function of allele frequency, age-related maculopathy susceptibility 2 (ARMS2), complement factor H (CFH), and complement component 3 (C3) harboured common but risky genetic variants. CFH and complement factor I also carried rare but high-risk alleles. Further research illustrated that variants in ARMS2, CFH and C3 indeed determine a large proportion of late AMD cases, while variants in C2 and other variants in CFH determine a large number of controls.

A positive genetic risk score was present in the majority of late AMD cases, but was also present in a significant fraction of controls. When calculating risk scores for complement, lipids, extracellular matrix and ‘other’ pathways, findings indicated that the average person with late AMD carries risk variants in at least three of these pathways.

Poor nutrition and smoking have also been confirmed as prominent risk factors for AMD. Unsurprisingly, a good diet and not smoking are vital to health regardless of AMD genetic risk category, however, both have the most positive influential effect in those at high genetic risk. Furthermore, Professor Klaver discussed a study of pooled data from the European Eye Epidemiology consortium which investigated serum lipids in 4600 AMD cases and 17000 controls, finding significant associations with HDLs (OR = 1.39, p<0.0001), LDLs (OR = 0.95, p=0.019), and triglycerides (OR = 0.89, p<0.0001). No or little physical exercise increased the risk of early and intermediate AMD.

The benefits of the Mediterranean diet in AMD were discussed by Emily Chew, Maryland, USA. Using dietary intake data from 7756 participants in the AREDS and AREDS2 studies, a dose response was identified, suggesting that a higher Mediterranean diet intake was associated with a 23%, 29%, and 16% reduction in risk of progression to late AMD, geographic atrophy, and neovascular AMD, respectively. In addition, fish intake was associated with a 31% decreased risk of progression to geographic atrophy (GA), and there was an increased beneficial effect of fish for those with protective alleles of CFH.

Eight proteins associated with normal ageing versus AMD were identified using gel eletrophoresis and mass spectrometry

Eight overlapping proteins associated with normal ageing versus AMD

Deborah Ferrington, Minnesota, USA, presented results from proteomic analyses of retinal pigment epithelium (RPE) from human donors during normal ageing versus donors exhibiting varying severities of AMD. Using 2D gel electrophoresis and mass spectrometry, the team were able to identify eight overlapping proteins associated with normal ageing versus AMD. However, significant divergence was observed between affected pathways: proteins involved in energy metabolism and signal transduction were observed to decrease with ageing while increasing in AMD. In contrast, protein metabolism, apoptosis and stress response were increased in AMD. These results highlight that separate cellular process underlie ageing and AMD.

“Ageing and AMD involve different cellular processes”

Deborah Ferrington, Minnesota, USA

Louise Porter, Strasbourg, France, explored the epigenetic mechanisms of gene regulation in AMD, reporting results from AMD-relevant epigenetic clock analyses and age-matched control RPE samples, ingenuity pathway analysis (IPA), and IPA causal network analysis. Epigenetic clocks demonstrated a deceleration of epigenetic age in RPE, and dysfunction in ageing-related epigenetic maintenance systems was found to underlie more frequent epigenetic aberrations. Furthermore, ageing-related epigenetic maintenance system dysfunction in the RPE may cause epigenetic aberrations to occur more frequently.

Considerations for current and future directions in ocular research

The current and future directions in ocular research

Twin studies in AMD reveal that the presence of risk variants does not define disease development. In a set of identical twins with the same risk loci at chromosomes 10 and 1, matched for epidemiological factors, one exhibited a severe form of AMD though his brother showed no evidence of AMD. This confirms that genetics do not explain 100% of AMD risk and it could be a multifactorial disorder, necessitating further understanding of epigenetic mechanisms. Margaret deAngelis, New York, USA, hypothesised that disruptions in DNA methylation processes may lead to alterations in gene expression and function. She also stressed the importance of a systems biology approach in AMD to help fine-tune targets most appropriate to validate for functional analyses, using this information to design personalised therapeutic targets for AMD in future.

Renata Puertas, London, UK, proposed that due to our ageing population and low AMD clinic discharge rates, the asynchronous model of non-face-to-face clinics is the best way forward for ophthalmology services in order to increase efficiency and effectiveness of ophthalmic care. Since AMD is easily monitored by imaging and earlier treatment facilitates better AMD outcomes, she suggests that a technician-led service with remote review by consultants may lend itself well to AMD virtual or digital care. Benefits of such would include:

Benefits of a technician-led service include early clinic visits, better identification of patients in need and shorter clinic visits

Benefits of a technician-led service with remote review by consultants

However, no direct contact with doctors and a possible extra appointment may pose disadvantages. Dr Puertas also reported that, when comparing face-to-face versus virtual clinics in AMD, no significant differences were identified in visual outcomes between groups (20/184.8 vs. 20/180.7, p=0.99) in those monitored for recurrence.

Objectives and advantages of a technician-led screening and monitoring service

Three objectives of a technician-led screening and monitoring service

The process of developing a reference map of genetic regulation of gene expression quantitative trait loci (eQTLs) and splicing quantitative trait loci (sQTLs) in AMD was described by Ayellet Segre, Massachusetts, USA. Her team used eQTL and sQTL data to begin to elucidate regulatory and causal mechanisms that underlie ocular diseases. In doing so, they found that eQTLs in the hypothalamus and amygdala are most strongly associated with AMD, suggesting a proxy for neuronal tissues in the retina. QTLs in lymphocytes and the liver may also propose roles in AMD for the immune system and lipid metabolism, respectively.

To further discern the aetiology of AMD, the team used LeafCutter to identify 98,616 splice events for 12,720 retinal genes. Around three-quarters of these splicing events were shared between peripheral and macula locations. Looking further into the tissue specificity distribution of these splicing events, around 7% of splicing events in 2605 genes were identified as retina-specific, and there was strong enrichment of tissue retina specificity amongst the rare inherited retina degeneration splicing events. Using a colocalisation method, they found AMD-associated genes proposed by retina sQTLs, including TBC1D23 and SNHG32, some of which were not found with retinal eQTLs. This suggests that genetic regulation of splicing for some of these genes may represent the underlying causal mechanism for AMD.

Lastly, the researchers looked beyond genome-wide significant associations in an attempt to find additional AMD associations amongst retinal sQTLs and eQTLs. They discovered that the AMD associations were most strongly enriched among the macular sQTLs, proposing 82 sQTLs and 216 eQTLs that may be associated with AMD.


Geographic atrophy

Geographic atrophy (GA) is the most common subtype of advanced AMD, and characterised by loss of RPE and choriocapillaris, and retinal and choroidal thinning. GA can lead to irreversible blindness, however, no effective therapies are currently in use for the disorder, and functional evaluation methods remain unreliable and time-consuming.

The role of mast cells

The role of mast cells

Gerard Lutty, Maryland, USA, described a rat model for assessing the role of choroidal mast cell degranulation in GA. Mast cells were stimulated for degranulation with 48/80, a snake venom-like compound, and were placed in hydrogel, which was subsequently inserted subconjunctivally. After 4–10 weeks, loss of RPE, reduced electroretinogram amplitude and retinal and choroidal thinning – all phenotypic characteristics of GA – were observed. Prevention of this phenotype was possible through the administration of oral ketotifen and a tryptase inhibitor, demonstrating that mast cell degranulation may represent a therapeutic target for GA.


Closing Remarks

Maureen Maguire

The ARVO annual meeting ended with closing remarks by Maureen Maguire, PhD, Pennsylvania, USA, the newly-installed ARVO President. Dr Maguire thanked all presenters and speakers for their contributions of important and innovative research and stated that, over the next years, we must continue to adjust, pivot, and adapt in order to navigate the many challenges of returning to the ‘new normal’.

“While this past year has provided many challenges for all of us, perseverance is the nature of our research community”

Maureen Maguire, Pennsylvania, USA

©Springer Healthcare 2021. This content has been independently selected and developed by Springer Healthcare and licensed by Roche for Medically. The topics covered are based on therapeutic areas specified by Roche. This content is not intended for use by healthcare professionals in the UK, US or Australia. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Opinions expressed do not reflect the views of Springer Healthcare. Springer Healthcare assumes no responsibility for any injury or damage to persons or property arising out of, or related to, any use of the material or to any errors or omissions. Please consult the latest prescribing information from the manufacturer for any products mentioned in this material.

ARVO 2022 will be taking place May 1st–5th in Denver, Colorado, USA